Literature DB >> 15184621

Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.

V Lampasona1, D Franciotta, R Furlan, S Zanaboni, R Fazio, E Bonifacio, G Comi, G Martino.   

Abstract

The authors used a liquid-phase radiobinding assay to measure serum anti-myelin oligodendrocyte protein (MOG) immunoglobulin (Ig) G in 87 patients with multiple sclerosis (MS), in 12 patients with encephalomyelitis, and in 47 healthy subjects. Anti-MOG IgM was determined in samples obtained at onset from 40 of 87 patients with MS and in control subjects. The frequency of positive samples with low titers of anti-MOG IgG (< or =5.7%) and IgM (< or =8.3%) was similar in all the groups and subgroups. Binding competition experiments showed that these antibodies had low affinity. Anti-MOG antibodies are not disease specific.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184621     DOI: 10.1212/01.wnl.0000127615.15768.ae

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  35 in total

1.  Anti-myelin antibodies in multiple sclerosis: clinically useful?

Authors:  C H Polman; J Killestein
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06       Impact factor: 10.154

Review 2.  Current understanding of the epidemiologic and clinical characteristics of optic neuritis.

Authors:  Masanori Nakazawa; Hitoshi Ishikawa; Taiji Sakamoto
Journal:  Jpn J Ophthalmol       Date:  2021-05-22       Impact factor: 2.447

Review 3.  B-cells and humoral immunity in multiple sclerosis. Implications for therapy.

Authors:  Sangjin Oh; Cornelia Cudrici; Takahiro Ito; Horea Rus
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

4.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

5.  An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis.

Authors:  Francesco Lolli; Barbara Mulinacci; Alfonso Carotenuto; Bruno Bonetti; Giuseppina Sabatino; Benedetta Mazzanti; Anna Maria D'Ursi; Ettore Novellino; Marta Pazzagli; Laura Lovato; Maria C Alcaro; Elisa Peroni; Maria C Pozo-Carrero; Francesca Nuti; Luca Battistini; Giovanna Borsellino; Mario Chelli; Paolo Rovero; Anna Maria Papini
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-12       Impact factor: 11.205

6.  Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology.

Authors:  Cecilia B Marta; Alfred R Oliver; Rebecca A Sweet; Steven E Pfeiffer; Nancy H Ruddle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-19       Impact factor: 11.205

7.  Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.

Authors:  Dun Zhou; Rajneesh Srivastava; Stefan Nessler; Verena Grummel; Norbert Sommer; Wolfgang Brück; Hans-Peter Hartung; Christine Stadelmann; Bernhard Hemmer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-01       Impact factor: 11.205

8.  Peptide reactivity between multiple sclerosis (MS) CSF IgG and recombinant antibodies generated from clonally expanded plasma cells in MS CSF.

Authors:  Xiaoli Yu; Don Gilden; Laura Schambers; Olga Barmina; Mark Burgoon; Jeffrey Bennett; Greg Owens
Journal:  J Neuroimmunol       Date:  2010-12-21       Impact factor: 3.478

9.  Role of pathogenic T cells and autoantibodies in relapse and progression of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in LEW.1AV1 rats.

Authors:  Yoh Matsumoto; Il-Kwon Park; Keiko Hiraki; Shin Ohtani; Kuniko Kohyama
Journal:  Immunology       Date:  2008-10-29       Impact factor: 7.397

10.  Autoantibodies to Non-myelin Antigens as Contributors to the Pathogenesis of Multiple Sclerosis.

Authors:  Michael C Levin; Sangmin Lee; Lidia A Gardner; Yoojin Shin; Joshua N Douglas; Chelsea Cooper
Journal:  J Clin Cell Immunol       Date:  2013-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.